Xenon Pharmaceuticals Announces Closing of its $63.0 Million Public Offering of Common Shares
September 17 2018 - 4:15PM
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage,
neurology-focused biopharmaceutical company, today announced the
closing of its previously announced public offering of 4,500,000
common shares pursuant to its existing shelf registration statement
at a public offering price of $14.00 per share. The gross proceeds
to Xenon from the offering, before deducting underwriting discounts
and commissions and other offering expenses payable by Xenon, were
$63.0 million.
Jefferies LLC and Stifel acted as joint
book-running managers for the offering. Bloom Burton
Securities Inc. acted as financial advisor to Xenon in connection
with the transaction.
A shelf registration statement relating to the
common shares offered in the public offering described above was
filed with the Securities and Exchange Commission (SEC) on December
7, 2015 and declared effective by the SEC on January 5, 2016. The
offering was made only by means of a written prospectus and
prospectus supplement that form a part of the registration
statement. A final prospectus supplement and accompanying
prospectus relating to the offering have been filed with the SEC
and are available on the SEC’s website at www.sec.gov. Copies of
the final prospectus supplement and the accompanying prospectus may
also be obtained by contacting Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, or by email at Prospectus_Department@Jefferies.com,
or by phone at (877) 821-7388; or from Stifel, Nicolaus &
Company, Incorporated, One Montgomery Street, Suite 3700, San
Francisco, California 94104, Attn: Syndicate, by telephone at (415)
364-2720 or by email at syndprospectus@stifel.com.
No securities were offered or sold, directly or
indirectly, in Canada or to any resident of Canada.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy the securities being
offered, nor shall there be any sale of the securities being
offered in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.
Xenon Investor/Media Contact:Jodi Regts Phone:
778.999.5634 Email: investors@xenon-pharma.com
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Xenon Pharmaceuticals (NASDAQ:XENE)
Historical Stock Chart
From Sep 2023 to Sep 2024